Stock Events

Stock Events

Agios Pharmaceuticals 

$27.21
46
-$0.35-1.27% Tuesday 20:00

Statistics

Day High
28
Day Low
26.93
52W High
45.49
52W Low
22.34
Volume
677,652
Avg. Volume
-
Mkt Cap
1.59B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

30JulExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Q1 2026
Next
-1.95
-1.78
-1.61
-1.44
Expected EPS
-1.606723
Actual EPS
N/A

Financials

-764.01%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
108.06MRevenue
-825.56MNet Income

Analyst Ratings

38.63Average Price Target
The highest estimate is 50.00.
From 8 ratings within the last 6 months. This is not an investment recommendation.
Buy
63%
Hold
38%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow AGIO. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
CRISPR Therapeutics
CRSP
Mkt Cap4.98B
CRISPR Therapeutics is involved in gene editing, a technology that could compete with Agios's approach to treating genetic diseases.
Vertex Pharmaceuticals
VRTX
Mkt Cap107.83B
Vertex Pharmaceuticals develops treatments for cystic fibrosis and other serious diseases, competing in the rare disease market space.
Gilead Sciences
GILD
Mkt Cap163.4B
Gilead Sciences has a broad portfolio including oncology, competing in the cancer treatment space where Agios is also active.
AMGEN
AMGN
Mkt Cap178B
Amgen focuses on human therapeutics, including treatments for cancer and cardiovascular disease, areas Agios is exploring.
Biomarin Pharmaceutical
BMRN
Mkt Cap10.45B
BioMarin Pharmaceutical specializes in enzyme replacement therapies for rare genetic disorders, directly competing with Agios's focus areas.
Sangamo Therapeutics
SGMO
Mkt Cap55.93M
Sangamo Therapeutics works on genomic medicine, including gene therapy, competing in the genetic disease treatment area.
Novartis
NVS
Mkt Cap279.67B
Novartis offers a wide range of healthcare solutions, including treatments for cancer and rare diseases, overlapping with Agios's market.
Alnylam Pharmaceuticals
ALNY
Mkt Cap39.51B
Alnylam Pharmaceuticals is a leader in RNAi therapeutics for rare genetic diseases, competing in the same niche as Agios.
Beam Therapeutics
BEAM
Mkt Cap3.15B
Beam Therapeutics specializes in precision genetic medicines using base editing, a novel approach that competes with Agios's strategies.

About

There is no Profile data available for 8AP.SG.
Show more...
CEO
Mr. Brian M. Goff M.B.A.
Employees
486
Country
United States
ISIN
US00847X1046

Listings

MU
DE
8AP.MU
STU
DE
8AP.STU
F
DE
8AP.F
BOATS
BOATS
AGIO.BOATS

0 Comments

Share your thoughts

FAQ

What is Agios Pharmaceuticals stock price today?▼
The current price of AGIO is $27.21 USD — it has decreased by -1.27% in the past 24 hours. Watch Agios Pharmaceuticals stock price performance more closely on the chart.
What is Agios Pharmaceuticals stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Agios Pharmaceuticals stocks are traded under the ticker AGIO.
Is Agios Pharmaceuticals stock price growing?▼
AGIO stock has fallen by -2.99% compared to the previous week, the month change is a -21.81% fall, over the last year Agios Pharmaceuticals has showed a -3.92% decrease.
What is Agios Pharmaceuticals market cap?▼
Today Agios Pharmaceuticals has the market capitalization of 1.59B
When is the next Agios Pharmaceuticals earnings date?▼
Agios Pharmaceuticals is going to release the next earnings report on July 30, 2026.
What were Agios Pharmaceuticals earnings last quarter?▼
AGIO earnings for the last quarter are -1.69 USD per share, whereas the estimation was -1.8 USD resulting in a +6.29% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Agios Pharmaceuticals revenue for the last year?▼
Agios Pharmaceuticals revenue for the last year amounts to 108.06M USD.
What is Agios Pharmaceuticals net income for the last year?▼
AGIO net income for the last year is -825.56M USD.
How many employees does Agios Pharmaceuticals have?▼
As of May 06, 2026, the company has 486 employees.
In which sector is Agios Pharmaceuticals located?▼
Agios Pharmaceuticals operates in the Health & Wellness sector.
When did Agios Pharmaceuticals complete a stock split?▼
Agios Pharmaceuticals has not had any recent stock splits.
Where is Agios Pharmaceuticals headquartered?▼
Agios Pharmaceuticals is headquartered in Cambridge, United States.